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Abstract
Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant
diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding
prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide
recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations
were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in
Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most
important protection for patients with malignant disease is the best-possible control of the underlying disease.
Introduction: SARS-CoV-2
SARS-CoV-2 is a novel betacoronavirus that has been first
identified in China in winter 2019 as the cause of a severe
inflammatory coronavirus infectious disease (COVID-19) of
the respiratory tract. Because its genome is closest related to
previously identified CoVs in bats, SARS-CoV-2 was ori-
ginally thought to represent a zoonosis. However, its rapid
spread in the human population suggests that SARS-CoV-2
is surprisingly well adapted to the human host hence
behaving like a new member of the community-acquired
respiratory viruses (CARVs). Similar to other CARVs, the
clinical presentation can range from a- and oligosymptomatic
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to full-blown influenza-like illness and primary viral pneu-
monia. For the purpose of these clinical recommendations,
manifestations of upper respiratory tract infectious disease
are diagnosed if there is at least one of the following: cough,
coryza, sore throat, shortness of breath AND a systemic
symptom/sign such as fever/malaise/myalgia AND labora-
tory confirmation by nucleic acid testing (NAT). Conversely,
lower respiratory tract infectious disease (LRTID) is diag-
nosed in patients with tracheitis and bronchitis, whereby
dyspnea and/or declining oxygen saturation at ambient air
often predict bi-lateral ground glass infiltrates seen earliest on
CT-scans, hence identifying viral pneumonia. Notably,
LRTID may occur early or late in the course and may rapidly
progress to life-threatening respiratory failure because of
massive impairment of gas-exchange. In addition, multi-
organ failure affecting renal and cardiac function have been
described. This life-threatening complication is thought to be
due to a hyperinflammatory process compatible with hemo-
phagocytic lymphohistiocytosis (HLH) [1, 2] in addition to
hypercoagulopathy leading to pulmonary embolism [3].
In general, CARVs follow a seasonality with influenza,
respiratory syncytial and parainfluenza viruses being the
most prominent ones [4]. Influenza and RSV can be treated
with specific antivirals, which is essential for the care of
infected cancer patients. Importantly, cancer patients with
CARV-infections are prone to co-infections, and bacterial/
fungal superinfections are the primary cause of CARV-
associated mortality in cancer patients [5].
Infection with SARS-CoV-2 has been described to occur
after an incubation period of about 3–5 days, with the most
common symptoms being raised temperature/fever and
cough [6]. Of note, the peak of clinical disease is in the 2nd
week with an increase in inflammation [7]. It is not clear if
cancer is a general risk factor for infection [6, 8, 9], but old
age, hypertension, and diabetes have clearly been defined as
risk factors for worse outcome [7]. Cancer patients should
also be assumed to have a worse prognosis [8] and pre-
liminary experience from Italy suggests that mortality in
patients with hematological malignancy may be as high as
20% (Livio Pagano, personal communication). However,
with regard to the present or upcoming outbreak of SARS-
CoV-2 accurate estimates regarding mortality and spread
are almost impossible to give since most factors influencing
the epidemiology are still unknown [10].
Specific aspects for hematologists and
oncologists
Clinicians caring for cancer patients during the SARS-CoV-
2 pandemic face a variety of challenges including the
management of cancer patients infected with SARS-CoV-2
as well as coping with a drastically changed work
environment due to emergency measures, staff sicknesses
and expected shortages of drugs, blood products, and
equipment for personal protection amongst others. In this
setting it appears wise to implement center-specific
standard-operating-procedures to define altered responsi-
bilities and access to care. Depending on the magnitude of
changes within a certain region, prioritization with regard to
anti-cancer therapy may be necessary to ensure the safe
administration of potentially dangerous and toxic treat-
ments. An example of these changed working conditions
may be that centers may automatically admit all patients
presenting with febrile temperature to an area dedicated to
the treatment of COVID-19 patients. If, however, a cancer
patient treated in the outpatient clinic presents with febrile
neutropenia and is admitted to the COVID-19 dedicated
area, the cancer patient may actually be at higher risk and
not receive the adequate therapy within the required time
frame in this emergency setting. It seems advisable to
envisage the situation of delivering care in a COVID-19-
dedicated area during the time of the most profound
immunosuppression caused by anti-cancer treatment. Some
elective therapies leading to profound immunosuppression
later on may be re-evaluated under the consideration that the
management of complications may be hampered because of
emergency measures. On the other hand, it is vital to ensure
appropriate cancer therapy as much as possible, especially
in patients with curative options and rapid proliferation of
their disease. Therefore, the individual situation of cancer
patients needs to be considered when implementing emer-
gency measures.
We have addressed some potential questions relevant for
clinicians caring for cancer patients in the following. We do
not address the topic of stem cell transplantation and cell
therapy, since this is the focus of guidelines prepared by the
European Society for Blood and Marrow Transplantation
which can be accessed under https://www.ebmt.org/ebmt/
news/coronavirus-disease-covid-19-ebmt-recommenda
tions-update-march-23-2020. Also, we do not provide spe-
cific recommendations as to structural changes within
departments caring for cancer patients because geographical
differences are too large to make generalized statements.
However, individual treatment decisions will have to take
these aspects into account and clinicians may have to
deviate from these recommendations due to reduced capa-
cities or other structural impediments.
(1) What is the risk for the patient to become infected
with SARS-CoV-2 and what is the risk for the patient to
have a severe disease course?
Currently available data does not show a different rate of
infection in patients with a malignant disease compared to
healthy members of the population [6, 7]. This is mostly
due to the fact that cancer patients as well as healthy indi-
viduals are immunologically naive to this novel pathogen.
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Regarding the course of the infection, underlying malignant
disease has not been identified as an independent risk factor
in multivariate analysis so far [7]. However, severely
immunosuppressed patients generally have a higher risk of
developing complications in CARV infections [11] and it
should be assumed that cancer patients are at risk of a more
severe course of COVID-19 as well [8]. In the absence of
more specific data, potential risk factors for a severe course
of the disease should be assumed as for other CARV-
infections: severe immunodeficiency, lymphopenia, long
and profound neutropenia, and older age [11]. As lym-
phopenia is a risk factor for LRTID and mortality in CARV
infections in SCT-recipients and SARS-CoV-2 appears to
cause or be associated with lymphopenia, patients with pre-
existing severe lymphopenia (<0.2 × 109/L) may in time be
shown to have an increased risk for a severe course of
COVID-19 as well [7, 11]. Clinicians should also be aware
that cancer patients generally shed CARV longer than
immunocompetent people [12] and this is probably true for
this novel coronavirus as well.
(2) What can be done to prevent COVID-19?
The most important measures are general contact pre-
cautions including hand hygiene. Patients should be coun-
selled regarding current recommendations of their local and
national health authorities. It is strongly advised that
patients with active malignant disease or currently on
treatment should stay away from any social gatherings,
especially in high-risk areas [8]. Also, all symptomatic
family members or those at high risk of early infection with
SARS-CoV-2 should stay away from patients with active
malignant disease or currently on treatment regardless of the
risk of corona. The aim is to prevent any infection with
CARV. Face masks can be offered for situations when
contact isolation is difficult, but patients should be aware of
a possibly false sense of security and never rely only on
them [13].
Good general health should be reinforced in cancer
patients. Patients should be advised regarding the impor-
tance of good general health: stop smoking, reduce weight
loss, physiotherapy, sufficient supply of vitamins like vita-
min C and D, and the treatment of any iron-deficiency.
Patients with secondary immunodeficiencies should be
evaluated if they require intravenous immunoglobulins
(ivIg) as recommended by EMA (recurrent infections in
patients with IgG < 4 g/l due to secondary immunodefi-
ciency) [14]. Physicians need to be aware that ivIg are NOT
specifically effective against SARS-CoV-2 because of lack
of specific antibodies within the product, but they help to
generally restore a defective immune response and help
to prevent additional (for example bacterial) infections.
As time elapses there is a high probability that new pre-
parations from immune donors will include protective
antibodies as well.
Prophylactic antibiotics and generous implementation of
G-CSF seem a logical attempt to avoid bacterial super-
infections and shorten the duration of severe immunosup-
pression. However, prior exposure to antibiotics has been
associated with adverse outcome in CARV-infections in
stem-cell transplant recipients [15]. Also, in geographical
areas with a high rate of multi-drug resistant bacteria, anti-
biotic prophylaxis is unlikely to work. G-CSF on the other
hand is known to be associated with the risk of hyperin-
flammation during regeneration. Thus, we strongly recom-
mend not to implement additional antimicrobial prophylaxis
on top of recent recommendations by current guidelines
concerning the use of antibiotics and G-CSF [16–18].
In contrast, vaccination against influenza and especially
pneumococci should be recommended for all cancer patients
as per current guidelines [19, 20].
(3) Who should have therapy for malignant disease
deferred or interrupted?
The most relevant and urgent question of clinicians is the
most difficult to answer: which anti-cancer therapies should
be deferred or interrupted and which should be given or
continued? We have attempted to provide a rationale
regarding the deferral or interruption of therapies in Fig. 1a,
b. Generally, patients with controlled underlying disease
have fewer infections than untreated patients [21], therefore,
uncontrolled malignant disease should be avoided and life-
threatening malignancy needs treatment, especially if there
is relevant curative potential. As stated above, impairments
and shortages due to the emergency situation need to be
taken into account. However, active malignant disease
should be treated accordingly and timely to prevent a
worsening in outcome. This includes surgical procedures
(for example for obstruction) as well as systemic anti-cancer
therapy or radiation.
Generally, treatment in asymptomatic patients should
continue as close to normal as possible. Prophylactic inter-
ruptions of continuous therapies are not generally recom-
mended. Many continuous therapies like for example BCR-
ABL targeting TKI are not associated with a clinically
relevant increase in immunosuppression and discontinuation
may impair control of the malignant disease. Also, clinicians
should be aware of the fact that termination of some drugs,
for example ruxolitinib, may have devastating effects in
terms of a rebound of symptoms [22]. On the other hand,
some therapies are associated with significant cytopenias and
toxicities which must be assumed as a risk factor for
the adverse outcome of COVID-19. In addition, as stated
above lymphopenia is likely a specific risk factor for adverse
outcome [7]. Therefore, the administration of drugs inhi-
biting B cells like monoclonal antibodies against CD20 is
possibly harmful and should be critically evaluated. Also,
drugs associated with hypersensitivity-phenomena may
aggravate COVID-19-induced hypersensitivity-pneumonitis
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[23]. Therefore, interruptions of some therapies may seem
prudent in patients presenting with symptoms of RTID.
In general, recommendations regarding the management of
potential infectious complications of novel and targeted
therapies should be observed [24, 25].
(4) How long should precautions last?
Precautions in individual cancer patients regarding ther-
apy should last until there are no more clinical signs of
ongoing infection and the patient has been tested negative.
Clinicians need to be aware of prolonged shedding of
CARV in cancer patients [12]. General precautions in the
population depend on guidance by national health autho-
rities. Some experts assume that the critical time of the
pandemic will last 2–4 months, if measures of clear-cut
social distancing are effectively maintained.
(5) What diagnostic measures should be taken in
somebody who shows symptoms of RTID/LRTID?
In someone presenting with symptoms of RTID, broad
diagnostics (ideally SARS-CoV-2 in addition to multiplex-
NAT including other CARV like influenza, parainfluenza,
metapneumo- and human coronaviruses, and respiratory
pathogens like pneumococci) is strongly recommended
A
B
Fig. 1 Management of therapy for malignant disease. a Proposed
algorithm for the management of anti-cancer therapy in patients with
active malignant disease. b Proposed algorithm for the management of
anti-cancer therapy in patients with chronic/controlled malignant dis-
ease. RTID respiratory tract infectious disease, LRTID lower respira-
tory tract infectious disease.
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[11, 26]. Identification of the infectious agent, even if it is not
SARS-CoV-2, has therapeutic and regulatory consequences
and should thus be obtained. We are aware that national
recommendations regarding testing for SARS-CoV-2 may
differ and that shortages of tests may become a problem.
However, we recommend that cancer patients should be
generously tested since it has immediate implications.
Samples should generally be taken from the involved
anatomical area. Nasopharyngeal aspirates, samples from
lower respiratory tract and nasopharyngeal swabs may be
used, nasal swabs alone confer a lower sensitivity [27].
Clinicians should be aware that testing for SARS-CoV-2
may produce false-negative results in asymptomatic or
mildly symptomatic patients and in patients with LRTID if
samples from the upper respiratory tract are tested [28, 29].
Therefore, it is very important to implement standardized
sampling and to repeat tests in patients with unexpected
results to avoid bias by pre-analytical mistakes. For diag-
nosis of LRTID in patients with CARV infection including
SARS-CoV-2, CT scans should be used rather than chest X-
ray [29–31]. If LRTID is present, patients should undergo
standard microbiological testing to test for bacterial or
fungal superinfection since superinfection is the most dan-
gerous complication in any CARV-infection [5].
(6) What general therapeutic measures should be
taken in somebody who is infected with SARS-CoV-2?
It seems logical to reduce immunosuppression in those
patients where this is possible. However, possible dis-
advantages should be taken into consideration like immune
reconstitution syndrome [1]. Therefore, in most cases it is
probably not prudent to stop immunosuppression. Steroids,
particularly high-dose, are generally associated with a pro-
longed shedding and an increased mortality in CARV-
infections [32, 33]. However, recent reports on COVID-19
suggest a benefit of steroid treatment [34] and low-dose
steroid (<1 mg/kg/day for 3 days) has been described in an
immunosuppressed patient [35]. A randomized trial is cur-
rently underway [36]. Thus, it seems reasonable to reduce
high doses of steroids to avoid profound immunosuppres-
sion by tapering to doses <1 mg/kg/day. As stated above,
ivIg-preparations to date are not specifically active against
SARS-CoV-2 and are therefore currently not recommended
as treatment.
Recent reports support a relevant proportion of hyper-
inflammation in severe cases of COVID-19 and suggest
the consideration of additional anti-inflammatory drugs
like tocilizumab or ruxolitinib in patients fulfilling the
criteria of HLH [1, 37–39]. Also, because of the increased
incidence of pulmonary embolism, anticoagulation is
strongly recommended [40].
(7) How can COVID 19 be treated specifically?
There are no established standard treatments for COVID-
19. Whenever possible, patients should be included into
clinical trials. Infectious disease specialists should be
involved in therapeutic decisions. If experimental treatment
with drugs approved for other indications is considered,
physicians should share the decision with the patients and
inform them about the chances and risks of such strategies.
Experiences with SARS and first experiences with
SARS-CoV-2 suggest the efficacy of some treatment
options [41]: lopinavir/ritonavir, chloroquine, and remde-
sivir seem most promising. Ribavirin is potentially effective
based on in silico models, but no clinical data is available.
For SARS, retrospective data with low quality of evidence
suggested the effectiveness of ribavirin in combination with
lopinavir/ritonavir.
If specific treatment is administered it should probably be
given as early as possible to be effective, similar to treat-
ment of influenza.
(8) What else should be considered?
Since cancer patients are particularly prone to severe
courses of CARV-infections, clinicians should be aware of
other CARV and other respiratory pathogens, which may
require specific treatment [11, 26, 42]. Also, co-infections
are much more common in cancer patients and as stated
above, cancer patients tend to take considerably longer to
clear the virus than healthy controls [12]. Often the question
is raised whether blood products may confer a risk of
infection—this does not seem to be the case. Therefore,
blood products are safe, although they might become rare
because of restrictions of donors.
Special aspects in pediatric hematology/
oncology
(9) What are the symptoms in children and how similar
are they to those in adults?
Clinical manifestation in healthy children has been
reported to be similar to adults, with cough and fever the
most frequent symptoms. Presentation is usually milder
than in adults. Rarely, also gastrointestinal symptoms such
as diarrhea, nausea, vomiting, and feeding difficulties may
be present [43]. In immunocompromised patients, some
possible differences may be noted due to lymphopenia and
pre-existing conditions (pulmonary cGvHD) (same as in the
adults) resulting in a more severe presentation and rapid
deterioration of the general condition.
(10) What is the risk of a child getting infected?
As shown by data from China, COVID-19 seems to
be uncommon in children (0.9–1.2%) compared to adults
[44].
(11) When should a child be tested and how?
Due to the clinical evidence of frequent mild onset and
evolution, only children with moderate-severe clinical condi-
tion admitted to the hospital for care are currently tested for
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COVID-19 infection (Italian experience, specific indications
could be different according to National Authorities). Due to
the atypical presentation and worse outcome in immuno-
compromised children, testing could be advised even with
mild symptoms (local strategy) because of possible therapeutic
implications. Diagnostic principles are the same as in adults
including additional work-up in all patients with LRTID.
(12) Should we screen all children before
chemotherapy?
Because of the indeterminate onset in children, some
centers may decide to screen all children prior to immu-
nosuppressive therapy. Another option could be to screen
children only if they are at high risk as defined by national
health authorities (for example recent contact with COVID-
19 positive person or if family members are symptomatic
(cough, fever, running nose, or diarrhea)).
(13) Special characteristics of the pediatric infection
There seems to be a persistence of positive rectal swab
even in asymptomatic children, which can lead to oral–fecal
transmission [45, 46]. Also, results from imaging proce-
dures may be moderately different [43, 47]. This should be
taken into account when local policies for management of
COVID-19 in the respective departments are devised.
Summary
COVID-19, caused by SARS-CoV-2, is expected to be a
devastating infection in patients with active cancer. It
should be taken seriously and managed rigorously without
jeopardizing the curative chance of individual cancer
patients. In view of the rapidly changing evidence and
general situation, we attempted to provide current and
clinically relevant guidance on the management of cancer
patients with or at risk of COVID-19.
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